US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · Respiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01 E adjuvant. In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
GSK Announces Positive Topline Data on Co-Administration of …
WEB3 days ago · PHILADELPHIA, September 18, 2024--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), both AS01-adjuvanted vaccines ...
GSK's Respiratory Syncytial Virus Vaccine Given Together With …
WEB3 days ago · Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
FDA advisers recommend world's first RSV vaccines, from Pfizer and GSK
WEBMar 1, 2023 · An FDA advisory committee has recommended that the agency approve two RSV vaccines for older people, one from Pfizer and another from GSK.
About Arexvy (Respiratory Syncytial Virus (RSV) vaccine ... - GSK
WEBJul 10, 2023 · Arexvy (Respiratory Syncytial Virus (RSV) vaccine, (recombinant, adjuvanted)) summary of product characteristics (SmPC) July 2023. Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time.
RSV vaccine: FDA approves GSK shot for older adults - CNBC
WEBMay 3, 2023 · The Food and Drug Administration approved GSK’s RSV vaccine for adults ages 60 and older. The GlaxoSmithKline shot is now the world’s first fully approved vaccine that targets respiratory ...
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
WEBJun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain...
Skip to content